Navigation Links
CoLucid Pharmaceuticals Names Linda Hogan VP of Business Development
Date:10/28/2008

cal and research objectives, and we are very pleased to bring Linda Hogan on board. Linda is a skilled and accomplished business development professional who is able to draw on a breadth of experience at Care Capital and Clearview to help advance CoLucid's partnering initiatives."

"I look forward to working with CoLucid to help identify key business targets and to set the future direction of CoLucid's product development and partnering strategies," said Hogan. "I am very excited about the market and partnering potential for the company's pipeline of innovative CNS product candidates."

CoLucid Pharmaceuticals recently announced positive results from its Phase II clinical study of its lead compound, COL-144, in the treatment of acute migraine. Findings from the study demonstrated that COL-144 is effective in relieving migraine headaches and is well tolerated.

COL-144 is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA) designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapy. COL-144 selectively targets 5-HT1F receptors expressed in the trigeminal nerve pathway. In addition to COL-144, CoLucid's pipeline includes a conjugated stigmine platform that has generated a series of preclinical candidates for the treatment of sleep/wake disorders, chronic pain, Alzheimer's disease and psychiatric disorders. COL-204, the lead compound in the conjugated stigmine program, is expected to enter clinical development in 2009 for wake promotion.

About CoLucid Pharmaceuticals, Inc.

CoLucid Pharmaceuticals was founded in December 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatment for central nervous system (CNS) disorders. The company's pipeline includes COL-144, a novel treatment for migraine headache, and a conjugated stigmine platform that has generated a series of preclinical candidates for t
'/>"/>

SOURCE CoLucid Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. CoLucid Pharmaceuticals Announces $25 Million Series B Financing for Advancement of First-in-Class Migraine Compound
2. Anadys Pharmaceuticals to Present at Bio Investor Forum
3. Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908
4. Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008
5. Avidas Pharmaceuticals Signs Agreement to Acquire North American Rights to Products That Address Chronic Dermatologic Conditions
6. Genesis Pharmaceuticals Received New Purchase Orders Worth $12 Million
7. ISTA Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Conference 2008
8. QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc.
9. Amylin Pharmaceuticals Diabetes Drug Byetta the Focus of California Lawsuit
10. Trubion Pharmaceuticals Announces Appointment of New Chief Medical Officer
11. MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... United States with 1 in 68 children currently affected with the disorder. For ... child on the road to recovery is extremely daunting. That’s where Talk About ...
(Date:7/28/2015)... FL (PRWEB) , ... July 16, 2015 (PRWEB) ... ... Insurance Agency, in Miami, FL, that specializes in providing Health insurance quotes to ... multiple carriers clients compare auto insurance rates that best suits their specific needs. ...
(Date:7/28/2015)... ... July 28, 2015 , ... Dr. Aziz Ahmad recently gave ... took place from noon to 1 p.m. Tuesday, June 23, at the Gulf Coast ... , Dr. Ahmad is board-certified in colorectal surgery and has more than 35 years ...
(Date:7/28/2015)... ... July 28, 2015 , ... Healthpointe ’s Cosmetic Laser Institute in Anaheim ... smooth state, and reduces the appearance of fine lines and wrinkles. , According to ... to instantly add volume to your cheek area to correct age-related volume loss in ...
(Date:7/28/2015)... ... , ... According to WFTV on July 15th heroin overdose rates ... cases. According to recent statistic Orlando suffers at least one death weekly as a ... heroin, and law enforcement officials are struggling to keep apace with its distribution. Officers ...
Breaking Medicine News(10 mins):Health News:National TACA Autism Conference Offers Hope and Help to Families Affected by Autism 2Health News:Nations Insurance Solutions Announces Auto, Motorcycle, and Commercial Business Insurance Quotes. 2Health News:Dr. Aziz Ahmad Delivers Talk at Gulf Coast Medical Center 2Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 2Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 3Health News:Heroin Overdose Deaths Increase by 270 Percent, Orlando Takes the Lead 2Health News:Heroin Overdose Deaths Increase by 270 Percent, Orlando Takes the Lead 3
... some experts, newly born neuronal stem cells in the adult ... these stem cells are to be utilized in this way, ... regulated. , A new study, led by Laurence Katz, ... of the North Carolina School of Medicine, suggests a way ...
... FALLS" , A study by Indiana University ... of their elderly study participants and their postural stability ... in line with recent findings by other researchers involving ... designed to probe cognitive function effective at identifying people ...
... of American,Physicians, Inc. (CAP) today announced that the exceptional ... has again,earned an A+ rating from A.M. Best Company, ... consecutive year that MPT has,achieved this rating., "We ... Rating again this year,",said CEO James L. Weidner. "It ...
... to millions of diabetics who are missed , , FRIDAY, ... for diabetes is being called for to help the ... disease, a new report says. , "Approximately 30 percent ... undiagnosed," study author Dr. Christopher Saudek, of Johns Hopkins ...
... & Asthma Network Mothers of Asthmatics Applauds FDA Public ... and Offers Critical Facts Patients Need to Know, ... their healthcare providers do not know that at the ... Today, FDA urged patients,still using chlorofluorocarbon (CFC) albuterol metered-dose ...
... EXTON, Pa., May 30 Isolagen(TM), Inc. (Amex:,ILE) ... notice from the staff,of the American Stock Exchange (AMEX) ... compliance did not demonstrate its ability,to regain compliance with ... (a)(i)-(iii) of the AMEX Company Guide within the,prescribed time ...
Cached Medicine News:Health News:Indiana University research at the American College of Sports Medicine annual conference 2Health News:Indiana University research at the American College of Sports Medicine annual conference 3Health News:Indiana University research at the American College of Sports Medicine annual conference 4Health News:Indiana University research at the American College of Sports Medicine annual conference 5Health News:Indiana University research at the American College of Sports Medicine annual conference 6Health News:Indiana University research at the American College of Sports Medicine annual conference 7Health News:Mutual Protection Trust Earns Third A+ Rating From A.M. Best 2Health News:Panel Calls for Better Diabetes Screening 2Health News:Get the Facts on the Albuterol Inhaler Transition 2Health News:Get the Facts on the Albuterol Inhaler Transition 3Health News:Isolagen, Inc. Reports Receipt of Initiation of Delisting Proceedings Notice from Amex 2Health News:Isolagen, Inc. Reports Receipt of Initiation of Delisting Proceedings Notice from Amex 3
(Date:7/28/2015)... -- Research and Markets ( ... "Craniomaxillofacial Implants Market - Global Industry Analysis, ... 2022" report to their offering. ... the current and future prospects of the global ... the global market due to increasing facial deformities ...
(Date:7/28/2015)...  SeraCare Life Sciences, a leading partner to ... the American Association of Clinical Chemistry (AACC) meeting ... the University of California, San Francisco (UCSF) for ... (T18) and Trisomy 13 (T13) trophoblast cell line ... materials for Non-Invasive Prenatal Testing (NIPT) of chromosomal ...
(Date:7/28/2015)... , July 28, 2015  PD-Rx Pharmaceuticals, ... announced that it has partnered with Dobson Technologies, ... as a Service (IaaS) product. PD-Rx ... practices across the United States.  Using Dobson Technologies, ... recovery and business continuity, ensure regulatory compliance, and ...
Breaking Medicine Technology:Global Craniomaxillofacial Implants (Plate and Screw Fixator Systems, Bone Graft Substitutes, Distraction Systems, and TMJ Replacement Devices) Market Analysis 2014-2022 2SeraCare Life Sciences Signs License Agreement with UCSF and Announces Early Access Program for Development of Aneuploidy Reference Materials 2SeraCare Life Sciences Signs License Agreement with UCSF and Announces Early Access Program for Development of Aneuploidy Reference Materials 3PD-Rx Partners With Dobson Technologies 2
... Cell Therapy, Inc. ("Pathfinder")(OTCQB: PFND), a biotechnology company focused ... damage, today announced that effective at the start of ... will change from SYMD to PFND.  The new ticker ... and has been approved by the Financial Industry Regulatory ...
... 2011 Cempra Pharmaceuticals today announced abstracts to ... novel fluoroketolide antibiotic, solithromycin (CEM-101), at the ... (ICAAC) , September 17 to 20, 2011, in ... the safety and routes of administration of CEM-101, ...
Cached Medicine Technology:Pathfinder Cell Therapy, Inc. Announces New Stock Ticker Symbol 2Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 3Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 4Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 5
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: